About: Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies
Creator	Kempf, Christoph Gröner, Albrecht Kreil, Thomas Pifat, Dominique Gajardo, Rodrigo Biesert, Lothar Dichtelmüller, Herbert Fabbrizzi, Fabrizio Jorquera, Juan Osheroff, Wendy Poelsler, Gerhard Von Hoegen, Ilka
Source	PMC
abstract	BACKGROUND: Solvent/detergent (S/D) treatment is an established virus inactivation technology that has been applied in the manufacture of medicinal products derived from human plasma for more than 20 years. Data on the inactivation of enveloped viruses by S/D treatment collected from seven Plasma Protein Therapeutics Association member companies demonstrate the robustness, reliability, and efficacy of this virus inactivation method. STUDY DESIGN AND METHODS: The results from 308 studies reflecting production conditions as well as technical variables significantly beyond the product release specification were evaluated for virus inactivation, comprising different combinations of solvent and detergent (tri(n‐butyl) phosphate [TNBP]/Tween 80, TNBP/Triton X‐100, TNBP/Na‐cholate) and different products (Factor [F]VIII, F IX, and intravenous and intramuscular immunoglobulins). RESULTS: Neither product class, process temperature, protein concentration, nor pH value has a significant impact on virus inactivation. A variable that did appear to be critical was the concentration of solvent and detergent. CONCLUSION: The data presented here demonstrate the robustness of virus inactivation by S/D treatment for a broad spectrum of enveloped test viruses and process variables. Our data substantiate the fact that no transmission of viruses such as human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or of other enveloped viruses was reported for licensed plasma derivatives since the introduction of S/D treatment.
has issue date	2009-05-20(xsd:dateTime)
bibo:doi	10.1111/j.1537-2995.2009.02222.x
has license	no-cc
sha1sum (hex)	7590f2f9c49cd344821b62e2c1472dd23537c35e
schema:url	https://doi.org/10.1111/j.1537-2995.2009.02222.x
resource representing a document's title	Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies
has PubMed Central identifier	PMC7187780
schema:publication	Transfusion
resource representing a document's body	covid:7590f2f9c49cd344821b62e2c1472dd23537c35e#body_text
is schema:about of	named entity 'detergent' named entity 'solvent' named entity 'Plasma' named entity 'data collection' named entity 'Protein' named entity 'cell culture' named entity 'detergent' named entity 'cell cultures' named entity 'pH 4' named entity '60 minutes' named entity 'IVIG' named entity 'virus' named entity 'HBV' named entity 'HCV' named entity 'virus' named entity 'vesicular stomatitis virus' named entity 'hepatitis C virus' named entity 'arthritis' named entity 'virus' named entity 'protein' named entity 'medicinal products' named entity 'enveloped viruses' named entity '2.0' named entity 'BVDV' named entity 'virus' named entity 'protein' named entity 'protein' named entity 'virus' named entity 'PRV' named entity 'Triton X-100' named entity 'detergent' named entity 'virus' named entity 'pH 8' named entity 'virus' named entity 'detergent' named entity '7.5' named entity 'infectivity' named entity 'IVIG' named entity 'virus' named entity 'virus' named entity 'protein' named entity 'virus' named entity 'virus' named entity 'virus' named entity 'infectivity' named entity 'IVIG' named entity 'IMIG' named entity 'viruses' named entity 'Tween 80' named entity 'Tween 80' named entity 'detergent' named entity 'virus' named entity 'detergents' named entity 'heat treatment' named entity 'viruses' named entity 'Triton X-100' named entity 'process variables' named entity 'incubation time' named entity 'IVIG' named entity 'HCV' named entity 'HBV' named entity 'virus' named entity 'protein' named entity 'virus' named entity 'VSV' named entity 'virus' named entity 'solvent' named entity 'virus' named entity 'cholate' named entity 'virus' named entity 'enveloped viruses' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software